These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 30621015)

  • 21. Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis.
    Wu Q; Mills EA; Wang Q; Dowling CA; Fisher C; Kirch B; Lundy SK; Fox DA; Mao-Draayer Y;
    JCI Insight; 2020 Feb; 5(3):. PubMed ID: 31935197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Siponimod in the treatment of multiple sclerosis.
    Goodman AD; Anadani N; Gerwitz L
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of siponimod on lymphocyte subsets in active secondary progressive multiple sclerosis and clinical implications.
    Spiezia AL; Scalia G; Petracca M; Caliendo D; Moccia M; Fiore A; Cerbone V; Lanzillo R; Brescia Morra V; Carotenuto A
    J Neurol; 2024 Jul; 271(7):4281-4291. PubMed ID: 38632126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-inflammatory effects of siponimod on astrocytes.
    Ogasawara A; Takeuchi H; Komiya H; Ogawa Y; Nishimura K; Kubota S; Hashiguchi S; Takahashi K; Kunii M; Tanaka K; Tada M; Doi H; Tanaka F
    Neurosci Res; 2022 Nov; 184():38-46. PubMed ID: 35940437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Siponimod to treat secondary progressive multiple sclerosis.
    Gajofatto A; Turatti M
    Drugs Today (Barc); 2020 Jan; 56(1):37-46. PubMed ID: 32055804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Siponimod (BAF312): General Characteristics and Clinical Implications of Pharmacogenomic Dosage in the Treatment of Active Secondary Progressive Multiple Sclerosis].
    Calfunao S; Carrasco M; Gutierrez C; Cerpa L; Varela N; Quiñones L
    Rev Med Chil; 2023 Oct; 151(10):1375-1384. PubMed ID: 39093141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation.
    Gruchot J; Lein F; Lewen I; Reiche L; Weyers V; Petzsch P; Göttle P; Köhrer K; Hartung HP; Küry P; Kremer D
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Siponimod from fingolimod direct switch in patients transitioning in secondary progressive multiple sclerosis: A single center case series.
    Bianco A; Guerra T; Caputo F; Paolicelli D; Iaffaldano P
    Clin Neurol Neurosurg; 2024 Oct; 245():108475. PubMed ID: 39159567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
    Selmaj K; Li DK; Hartung HP; Hemmer B; Kappos L; Freedman MS; Stüve O; Rieckmann P; Montalban X; Ziemssen T; Auberson LZ; Pohlmann H; Mercier F; Dahlke F; Wallström E
    Lancet Neurol; 2013 Aug; 12(8):756-67. PubMed ID: 23764350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targets of therapy in progressive MS.
    Lassmann H
    Mult Scler; 2017 Oct; 23(12):1593-1599. PubMed ID: 29041864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ibudilast for the treatment of multiple sclerosis.
    Goodman AD; Gyang T; Smith AD
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1231-7. PubMed ID: 27501293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Siponimod Chips Away at Progressive MS.
    Longbrake EE; Hafler DA
    Cell; 2019 Dec; 179(7):1440. PubMed ID: 31951523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Siponimod (BAF312) Treatment Reduces Brain Infiltration but Not Lesion Volume in Middle-Aged Mice in Experimental Stroke.
    Vogelgesang A; Domanska G; Ruhnau J; Dressel A; Kirsch M; Schulze J
    Stroke; 2019 May; 50(5):1224-1231. PubMed ID: 31009359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sphingosine 1-Phosphate Receptor Subtype 1 as a Therapeutic Target for Brain Trauma.
    Cuzzocrea S; Doyle T; Campolo M; Paterniti I; Esposito E; Farr SA; Salvemini D
    J Neurotrauma; 2018 Jul; 35(13):1452-1466. PubMed ID: 29310513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy-A case series.
    Zanghì A; Di Filippo PS; Avolio C; D'Amico E
    Mult Scler Relat Disord; 2024 Oct; 90():105795. PubMed ID: 39151236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function.
    Ontaneda D; Thompson AJ; Fox RJ; Cohen JA
    Lancet; 2017 Apr; 389(10076):1357-1366. PubMed ID: 27889191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the horizon: possible neuroprotective role for glatiramer acetate.
    Kreitman RR; Blanchette F
    Mult Scler; 2004 Jun; 10 Suppl 1():S81-6; discussion S86-9. PubMed ID: 15218816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short- and long-term effects of siponimod on autonomic nervous system in secondary progressive multiple sclerosis.
    Habek M; Junaković A; Karić A; Crnošija L; Barun B; Gabelić T; Adamec I; Krbot Skorić M
    Mult Scler Relat Disord; 2022 Aug; 64():103966. PubMed ID: 35724530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Siponimod: First Global Approval.
    Al-Salama ZT
    Drugs; 2019 Jun; 79(9):1009-1015. PubMed ID: 31144287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapies: Progressive steps.
    Dolgin E
    Nature; 2016 Nov; 540(7631):S7-S9. PubMed ID: 27902682
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.